MediWound (MDWD)

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

的MediWound Ltd. Ordinary Shares（MDWD）股票的价格今天是$17.21，自市场开启。该公司市值为$2.21亿，日交易量为股。前一交易日收盘价为 $17.21。

您准备好开始了吗？按照以下步骤操作，或阅读我们关于在Kraken上从10美元起购买MediWound股票的指南。